Biodexa holds first FAP round table in Paris to expand patient support
Biodexa Pharmaceuticals PLC held its first round table meeting in Paris to expand support for Familial Adenomatous Polyposis (FAP) patients and prescribers. The initiative complements the company's Early Access Program for eRapa, aiming to improve patient outcomes through shared expertise among clinicians and patients.
*this image is generated using AI for illustrative purposes only.
Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) held its first round table meeting in Paris, France, on July 28, 2026, to expand support for patients with Familial Adenomatous Polyposis (FAP) and their prescribers. The clinical-stage biopharmaceutical company stated that this engagement aims to improve outcomes and quality of life by facilitating the sharing of experience and expertise among patients, advocacy groups, and clinicians. This strategic step augments Biodexa’s previous initiative of making its investigational medicine, eRapa, available for FAP patients via an Early Access Program and Named Patient prescribing.
Stephen Stamp, Chief Executive Officer of Biodexa, said the company is committed to improving the lives of patients and supporting clinicians who treat individuals with no currently approved therapeutic options. The round table activities are designed to complement the availability of eRapa, ensuring that prescribers have both the medicinal tool and a community-supported knowledge base necessary for effective patient management.
Strategic Support for FAP Patients
Biodexa’s approach integrates multiple support mechanisms to assist both patients and healthcare providers. The company is leveraging insights from these collaborative sessions to refine its support structures. The key components of this expanded support framework include:
| Initiative Component | Description |
|---|---|
| Round Table Meetings | First session held in Paris, France, involving patients, advocacy groups, and clinicians. |
| Early Access Program | Provides access to investigational eRapa outside of clinical trials. |
| Named Patient Prescribing | Allows clinicians to prescribe eRapa for individual FAP patients globally. |
| Expertise Sharing | Facilitates knowledge exchange to inform treatment strategies and improve quality of life. |
The sharing of experience among stakeholders is informing Biodexa’s goal of improving outcomes. These activities complement the availability of eRapa, ensuring that prescribers have both the medicinal tool and the community-supported knowledge base necessary for effective patient management.
What the Numbers Show
While this announcement focuses on operational and patient-support initiatives rather than financial metrics, the expansion of the Early Access Program signals Biodexa’s commitment to real-world evidence generation. The ability to prescribe eRapa outside of clinical trials represents a significant milestone in the drug’s development lifecycle, potentially accelerating data collection on efficacy and safety in a broader patient population. This move may influence future regulatory discussions and commercial strategy for eRapa in treating gastrointestinal conditions such as FAP.
How will the real-world evidence generated through the Early Access Program and Named Patient prescribing influence the FDA's or EMA's regulatory approval timeline for eRapa?
What specific financial metrics or milestones should investors monitor to assess the commercial viability of eRapa following this expanded patient access initiative?
Will Biodexa plan to expand these round table meetings to other key markets outside of Europe, such as the United States or Asia, to support global regulatory submissions?
16
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
